BioX­cel looks to ex­pand la­bel to at-home use for lead psych drug. Ini­tial da­ta are mixed

BioX­cel re­port­ed Thurs­day morn­ing that Igal­mi, a drug ap­proved to treat ag­i­ta­tion in pa­tients with cer­tain psy­chi­atric dis­or­ders, had mixed re­sults in the first part of a Phase III study.

The biotech hopes to use the study to ex­pand Igal­mi’s la­bel so the drug can be used at home — and would not have to be ad­min­is­tered with a health­care provider present.

At two hours post-treat­ment, peo­ple who re­ceived the drug did not per­form sig­nif­i­cant­ly dif­fer­ent­ly on a scale that mea­sures ag­i­ta­tion from those who re­ceived place­bo — but the p-val­ue just bare­ly missed the cut at 0.077. But at four hours post-treat­ment, there was more sep­a­ra­tion be­tween the two groups, and with a p-val­ue of 0.049, the dif­fer­ence was sta­tis­ti­cal­ly sig­nif­i­cant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER